Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Neurology and Neurosurgery
  • Neurology & Neurosurgery News
  • Lowering LDL...

Lowering LDL cholesterol < 70 mg/dL with Statin and Ezetimibe combo reduces stroke risk: "Treat Stroke to Target" Trial

Written By : Aditi |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-10-15T09:45:12+05:30  |  Updated On 18 Oct 2023 3:50 PM IST
Lowering LDL cholesterol < 70 mg/dL with Statin and Ezetimibe combo reduces stroke risk: Treat Stroke to Target Trial
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

FRANCE: The results of a post hoc analysis done by a team of researchers concluded that targeting LDL cholesterol of < 70 mg/dL with a dual therapy of statin and ezetimibe compared with 100±10 mg/dL reduces the risk of subsequent stroke in the TST (Treat Stroke to Target) trial.

The study findings are published in the AHA journal "STROKE."

The first trial focusing on cholesterol reduction was the SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Level) randomizing 4731 patients with a history of recent stroke to atorvastatin 80 mg and it lowered 16% risk of stroke (adjusted hazard ratio, 0.84) after 4.9 years. The second trial after this is the TST Trial.

Putting high-risk stroke patients on maximal statin therapy (fire-and-forget) or adjusting treatment to achieve a target LDL cholesterol (treat-to-target) is a matter of debate even after years of SPARCL.

"Addition of ezetimibe to statin therapy lowers LDL-C and reduces the risk for stroke in patients of the acute coronary syndrome.", as interpreted by IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).

According to the American College of Cardiology and the American Heart Association, patients with clinical atherosclerotic cardiovascular disease, including ischemic stroke, receive high-dose statin therapy. The patients at very high risk (multiple major atherosclerotic cardiovascular disease events and additional vascular risk factors) are recommended to target LDL-C to <70 mg/dL by additional agents. These guidelines are supported by TST and mention that lower LDL target levels are achievable with statins with or without ezetimibe, but "LDL-C goal is more important than the choice of statin." This is similar to what is mentioned in the European Society of Cardiology 2020 guidelines.

Considering this, a post hoc analysis was performed by Dr. Pierre Amarenco, MD, at the Department of Neurology and Stroke Centre at Bichat Hospital with a team of researchers to determine the relative effects of dual therapy of statin and ezetimibe and statin monotherapy to achieve lower LDL cholesterol target and reduce the significant vascular events risk. A comparison was made with the higher target group.

The study included schemic stroke patients in the previous three months or had transient ischemic attacks within the last 15 days and a history of cerebrovascular or coronary artery atherosclerosis. The primary outcome measured was the major cardiovascular event. The secondary results measured were myocardial infarction and urgent coronary revascularization, cerebral infarction and urgent carotid and cerebral artery revascularization and intracranial haemorrhage.

In statistical analysis, the Cox regression model was included.

The critical points of the study are:

• 2860 patients enrolled in the study.

• The dual therapy (statin plus ezetimibe) had 529 patients.

• The monotherapy had 896 patients.

• The patients targeting LDL cholesterol < 70mg/dL were compared to those targeting 100±10 mg/dL. This had 1424 patients.

• Patients on dual therapy had a higher baseline LDL cholesterol of 141±38.

• The patients on statin monotherapy had lower baseline LDL cholesterol levels than the dual therapy and were 131±36.

• The achieved LDL cholesterol in patients on dual therapy and monotherapy was 66.2 and 64.1 mg/dL, respectively.

• The primary outcome of dual therapy had a Hazard Ratio of 0.59 and was reduced compared with the higher target group. The P value was 0.016.

• The primary outcome was not reduced in statin monotherapy with HR of 0.92 and P value of 0.56

• Myocardial infarction and urgent coronary revascularization had HR of 0.36 with a P value of 0.057 in dual therapy and 0.87 with a P value of 0.67 in monotherapy.

• The HR for dual therapy was 0.57 (P value 0.037) and 0.93 (P value 0.79 ) for cerebral infarction and urgent carotid and cerebral artery revascularization.

• The intracranial haemorrhage had an HR of 0.62 in dual therapy and 0.95 for monotherapy. The p-values were 0.023 and 0.74, respectively.

• There was no significant increase risk of intracranial bleeding with dual therapy.

Dr. Jong S. Kim said that we support the use of dual therapy. In this secondary analysis of the TNT trial, we recorded a lower risk of major adverse cardiovascular events and the composite of stroke and urgent carotid and cerebral artery revascularization in patients receiving dual therapy to achieve the target of LDL cholesterol <70 mg/dL compared to the patients targeting 100 ± 10 mg/dL.

Reference:

Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial Pierre Amarenc Stroke. 2022;0:10.1161/STROKEAHA.122.039728

dual therapycombined statin and ezetimibestatin monotherapystroke- aha journalTREAT STROKE TO TARGET TRIAL
Source : AHA JOURNALS-STROKE
Aditi
Aditi

    BDS, MDS in Periodontics and Implantology

    Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    National Consensus 2025 on Role of Bisoprolol Across CV Continuum in Women: Top 10 Takeaways

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Relevance of Pioglitazone in Indian T2DM Care Continuum

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    First Indian Consensus on Managing Refractory Gastroesophageal Reflux Disease Recommends Vonoprazan

    View All

    Journal Club Today

    Study Shows Combination Therapy May Improve Survival in Severe Heart Disease

    Study Shows Combination Therapy May Improve Survival in Severe Heart Disease

    View All

    Health News Today

    Health Bulletin 04/June/2025

    Health Bulletin 04/June/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok